No HER3-targeted drugs have been approved to date, but there are dozens of candidates in clinical testing, so the pressure is on MSD and Daiichi Sankyo to get patritumab deruxtecan to market as ...

2-Year U.S. Treasury Note Continuous Contract $103.605-0.004 0.00% 5-Year U.S. Treasury Note Continuous Contract $108.016 0.039 0.04% 10-Year U.S. Treasury Note Continuous Contract $110.672 0.063 ...

2-Year U.S. Treasury Note Continuous Contract $103.625 0.016 0.02% 5-Year U.S. Treasury Note Continuous Contract $108.063 0.086 0.08% 10-Year U.S. Treasury Note Continuous Contract $110.766 0.156 ...